Provision of random-donor platelets (HPA-1a positive) in neonatal alloimmune thrombocytopenia due to anti HPA-1a alloantibodies.

Abstract

AbstractMost cases of neonatal alloimmune thrombocytopenia (NAIT) are diagnosed after birth and infants with severe NAIT remain at risk for intracranial haemorrhage [1]. In suspected severe NAIT cases, treatment must be instituted prior to confirmation of the diagnosis. HPA‐1a alloimmunisation is the most common cause of NAIT. The most effective forms of treatment are provision of compatible antigen‐negative platelets or provision of maternal platelets [2].